Kenvue, a consumer-health company, narrowly missed Wall Street estimates for second-quarter results on Thursday as inflation, tariffs, and currency-related costs squeezed margins.
Quarterly Results
The maker of Tylenol painkillers and Neutrogena skincare products posted second-quarter adjusted profit of 31 cents per share, marginally below analysts’ average estimate of 32 cents.
Quarterly sales rose 3% to $3.96 billion, but slightly missed analysts’ estimate of $3.97 billion.
Kenvue’s adjusted gross margin fell to 60.2% from 60.9% a year earlier, as inflation, tariffs, and currency-related costs outweighed some of the benefits from supply-chain savings and higher prices.
The company expects about $250 million in pre-tax charges in 2026 from a restructuring program aimed at simplifying operations, improving its supply chain, and lowering costs.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
